PSCA and non-small cell lung carcinoma: In a non-small cell lung cancer (NSCLC) model, a therapeutic combination of CAR T-cells targeting prostate stem cell antigen (PSCA) and mucin 1 (MUC1) effectively eradicated cancer cells expressing PSCA and MUC1 [122].